This abstract will be presented at a press conference, “Treatment and Resistance to Targeted Therapies,” hosted by Levi Garraway, M.D., Ph.D., assistant professor of medicine in the department of medical oncology at the Dana-Farber Cancer Institute, at 2 p.m. ET on April 7 in Room 153 of the Walter E. Washington Convention Center. Reporters who cannot attend in person can call in using the following information:• U.S./Canada (toll free): 1 (800) 446-2782• International (toll call): 1 (847) 413-3235
Newswise — WASHINGTON, D.C. — Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.
“It was exciting to witness the discovery of BRAF mutations in melanoma and the translation of this discovery into an effective therapy with vemurafenib,” said Darrin Stuart, Ph.D., senior research investigator at the Novartis Institutes for Biomedical Research in Emeryville, Calif. “It was, however, disappointing to see patients stop responding to such a promising therapy after six to eight months of treatment.”
BRAF mutations are found in more than half of all cases of melanoma, and previous studies have shown vemurafenib increases survival for these patients, according to Stuart. However, most patients relapse with lethal, drug-resistant disease.
In a previous study to investigate the mechanisms causing melanomas to become resistant to vemurafenib, Stuart and his colleagues grew patient-derived tumors expressing BRAF mutations in mice and demonstrated that not only do these tumors develop vemurafenib resistance, but they become dependent on the drug to grow. Tumors stopped growing and regressed after cessation of the drug in these animals.
To evaluate whether the drug dependency observed in animals is seen in humans as well, Stuart and his team collaborated with colleagues who evaluated 42 patients with vemurafenib-resistant tumors at the Royal Marsden Hospital in London, United Kingdom. Computed tomography scans of the tumors taken after cessation of treatment were available for 19 patients. Of these patients, 14 showed a decrease in the rate of their tumor growth.
“This is the first evidence that the drug-addicted state that we observed in our mouse models may also occur in humans,” said Stuart.
He and his colleagues also implanted mice with human patient-derived tumors and treated them with vemurafenib either continuously or intermittently — four weeks on and two weeks off. They found that none of the tumors in animals assigned to intermittent dosing developed drug resistance.
“Continuous dosing maintained the selective pressure required for the few surviving tumor cells to develop resistance, and alternating the selective pressure through intermittent dosing appeared to prevent the evolution and expansion of resistant cells,” said Stuart. “This study provides insight into how vemurafenib-resistant tumors evolve. Alternative dose regimens could prolong the durability of response to vemurafenib in BRAF-mutant melanoma.”
###
Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers: www.aacr.org/PressRegistration.
Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org
About the American Association for Cancer ResearchFounded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
Abstract Number: LB-144
Presenter: Darrin Stuart, Ph.D.
Title: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Authors: Meghna Das Thakur, Rosalie Fisher, Fernando Salangsang, Allison S. Landman, William R. Sellers, Nancy K. Pryer, Mitchell P. Levesque, Reinhard Dummer, Martin Gore, James Larkin, Martin McMahon & Darrin D. Stuart
Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumors expressing the BRAF (V600E) oncoprotein. Moreover, the impressive tumor regression and increased survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance. Although vemurafenib therapy has transformed the treatment of late-stage melanoma patients, the durability of patient response to this drug is limited by the emergence of lethal drug resistant disease. Thus, understanding mechanisms and designing approaches to prevent the emergence of resistance are critical to providing improved therapy.
Here we model the emergence of vemurafenib resistance using two early passage primary human-patient-derived xenograft (PDX) BRAF(T1799A)-mutated melanoma models, which were continuously treated with vemurafinib in immunocompromised mice. In one of these models vemurafenib resistance is due to selection of cells with elevated expression of the BRAF(V600E) oncoprotein. Remarkably, vemurafenib resistant tumors are not only drug resistant but also develop drug dependency such that tumors require exposure to vemurafenib for their continued proliferation. Indeed, cessation of drug administration in these PDX models leads to inhibition of tumor growth and, in many cases, tumor regression. This fitness deficit upon cessation of drug administration is based on an adaptive response to levels of MAPK pathway signaling output. Melanoma cells appear to proliferate best at a defined intermediate level of RAFMEKERK signaling output. Hence, when drug resistant tumor cells are deprived of drug, the level of signaling output is increased leading to decreased proliferation.
We sought to determine whether vemurafenib-resistant tumors in melanoma patients displayed similar evidence of drug dependency. In a small cohort of patients (n=42) with vemurafenib-resistant tumors for which CT scans were available following cessation of treatment (n=19), 14 out of 19 patients demonstrated evidence of reduced tumor growth velocity. Taken together, these data support the hypothesis that continuous treatment with vemurafenib can select for drug-resistant tumor cells that show a fitness deficit in the absence of the drug. Furthermore, we demonstrate in the pre-clinical setting that these observations can be leveraged therapeutically by using a discontinuous treatment regimen to forestall the emergence of resistance in two different PDX models. Consequently, these data may have important implications for the treatment of BRAF mutated melanoma patients with BRAF (V600E) inhibitors and suggest that altered dosing might delay or prevent the emergence of lethal drug resistant disease.
RSS